^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FLT4 overexpression

    i
    Other names: FLT4, PCL, VEGFR3, Fms-related tyrosine kinase 4
    Entrez ID:
    2324
    Related biomarkers:
    Mutation
    CNA
    Others
    11ms
    Dauricine Inhibits Non-small Cell Lung Cancer Development by Regulating PTEN/AKT/mTOR and Ras/MEK1/2/ERK1/2 Pathways in a FLT4-dependent Manner. (PubMed, Curr Cancer Drug Targets)
    Dauricine may be a promising FLT4 inhibitor for the treatment of NSCLC.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • FLT4 (Fms-related tyrosine kinase 4) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
    |
    FLT4 overexpression
    almost2years
    High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. (PubMed, Int J Mol Sci)
    Our results suggest that the levels of this receptor could be a potential marker of meager doxorubicin response. Consequently, our results suggest that the combination of chemotherapy and VEGFR3 blockage could be a potentially useful therapeutic strategy for the treatment of triple-negative breast cancer.
    Journal
    |
    FLT4 (Fms-related tyrosine kinase 4)
    |
    FLT4 overexpression
    |
    doxorubicin hydrochloride